In order to evaluate the biological and clinical implication of these findings, testing EZH2 inhibitors and SM combination in preclinical GBM models, and a complete understanding of molecular pathways modulated by such treatment, is warranted. The gene discussed is EZH2; the disease is glioblastoma.